

Uveamelanom

Mitglieder Komitee „Uveamelanom“



Markus Heppt,
Erlangen
(Sprecher)



Lucie
Heinzerling,
München



Konstantin
Drexler,
Regensburg



Andrea
Forschner,
Tübingen



Jessica Hassel,
Heidelberg
(Sprecherin)



Max
Schlaak,
Berlin



Armin
Bender,
Marburg



Martin
Gschnell,
Marburg



Anja
Wessely,
Erlangen

Aktuelle Projekte

- Mitarbeit Leitlinie ESMO und im Rahmen der neuen S3-Leitlinie Melanom
- Mitarbeit Infoportal Hautkrebs: Sonderformen/Aderhautmelanom; Erstellung einer Patientenbroschüre
- Versorgungsforschung zur Verbesserung und Standardisierung der Nachsorge
- Untersuchung der Kombination aus leberspezifischen Therapien und Systemtherapie im fortgeschrittenen Aderhautmelanom
- Aufbau eines Patientennetzwerks

Uveamelanom

Publikationen 2022-2023

Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial.

Carvajal RD, Butler MO, Shoushtari AN, **Hassel JC**, Ikeguchi A, Hernandez-Aya L, Nathan P, Hamid O, Piulats JM, Rioth M, Johnson DB, Luke JJ, Espinosa E, Leyvraz S, Collins L, Goodall HM, Ranade K, Holland C, Abdullah SE, Sacco JJ, Sato T. Nat Med. 2022 Nov;28(11):2364-2373.

Clinical determinants of long-term survival in metastatic uveal melanoma.

Koch EAT, Petzold A, Wessely A, Dippel E, Erdmann M, **Heinzerling L**, Hohberger B, Knorr H, Leiter U, Meier F, Mohr P, Rahimi F, Schell B, **Schlaak M**, Terheyden P, Schuler-Thurner B, Ugurel S, Utikal J, Vera J, Weichenthal M, Ziller F, Berking C, **Heppt MV**. Cancer Immunol Immunother. 2022 Jun;71(6):1467-1477. doi: 10.1007/s00262-021-03090-4. Epub 2021 Oct 28. PMID: 34709438

Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trial.

Koch EAT, Petzold A, Wessely A, Dippel E, Eckstein M, Gesierich A, Gutzmer R, **Hassel JC**, Knorr H, Kreuzberg N, Leiter U, Loquai C, Meier F, Meissner M, Mohr P, Pföhler C, Rahimi F, Schadendorf D, Schlaak M, Thoms KM, Ugurel S, Utikal J, Weichenthal M, Schuler-Thurner B, Berking C, **Heppt MV**. Front Med. 2023 Jul 4. doi: 10.1007/s11684-023-0993-y. Epub ahead of print. PMID: 37432641.

Uveamelanom

Publikationen 2022-2023

S100 as Serum Tumor Marker in Advanced Uveal Melanoma.

Salzmann M, Enk AH, **Hassel JC**. Biomolecules. 2023 Mar 14;13(3):529. doi: 10.3390/biom13030529. PMID: 36979464

Is tebentafusp superior to combined immune checkpoint blockade and other systemic treatments in metastatic uveal melanoma? A comparative efficacy analysis with population adjustment.

Petzold A, Steeb T, Wessely A, Koch EAT, Vera J, Berking C, **Heppt MV**. Cancer Treat Rev. 2023 Apr;115:102543. doi: 10.1016/j.ctrv.2023.102543.

Practical guidelines for the management of adverse events of the T cell engager bispecific tebentafusp.

Hassel JC, Berking C, Forschner A, Gebhardt C, **Heinzerling L**, Meier F, Ochsenreither S, Siveke J, Hauschild A, Schadendorf D. Eur J Cancer. 2023 Sep;191:112986. doi: 10.1016/j.ejca.2023.112986. Epub 2023 Jul 11. PMID: 37595494

Tebentafusp in Patients with Metastatic Uveal Melanoma: A Real-Life Retrospective Multicenter Study.

Tomsitz D, Ruf T, **Heppt M**, Staeger R, Ramelyte E, Dummer R, Garzarolli M, Meier F, Meier E, Richly H, Gromke T, Siveke JT, Franklin C, Klespe KC, Mauch C, Kilian T, Seegräber M, Schilling B, French LE, Berking C, **Heinzerling L**. Cancers (Basel). 2023 Jun 30;15(13):3430. doi: 10.3390/cancers15133430.